You just read:

Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University

News provided by

Lixte Biotechnology Holdings, Inc.

Dec 30, 2015, 09:35 EST